Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Malignant Neoplasms of Female Genital Organs
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03531645
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
Phase 3
Active, not recruiting
- Conditions
- Metastatic Malignant NeoplasmAdvanced Malignant NeoplasmRecurrent Malignant Neoplasm
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Physical ActivityOther: PlaceboOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 212
- Registration Number
- NCT03525873
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Phase 1
Completed
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03524170
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy
Completed
- Conditions
- Lung NeoplasmMalignant Neoplasms of Respiratory and Intrathoracic Organs
- Interventions
- Procedure: BronchoscopyProcedure: Radial Probe Endobronchial Ultrasound
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT03523689
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment
Not Applicable
Active, not recruiting
- Conditions
- Current Every Day SmokerTobacco Use DisorderDepression
- Interventions
- Other: Internet-Based InterventionOther: Questionnaire Administration
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03519451
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2
Terminated
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
- Interventions
- Biological: BlinatumomabBiological: FilgrastimOther: Laboratory Biomarker AnalysisBiological: PegfilgrastimBiological: Rituximab
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03518112
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
Phase 1
Completed
- Conditions
- Malignant Peritoneal NeoplasmMetastatic Cervical CarcinomaMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaMalignant Retroperitoneal NeoplasmMetastatic Malignant Female Reproductive System NeoplasmPeritoneal Carcinomatosis
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacokinetic Study
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT03508570
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction
Not Applicable
Completed
- Conditions
- Mammoplasty Patient
- Interventions
- Other: Questionnaire AdministrationProcedure: Reconstructive Surgery
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03502512
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome
Not Applicable
Completed
- Conditions
- High-Frequency Microsatellite InstabilityMutation-Negative Lynch SyndromeMutation-Positive Lynch SyndromeMismatch Repair Gene Mutation
- Interventions
- Other: Informational InterventionBehavioral: Exercise InterventionDevice: Monitoring DeviceOther: Questionnaire Administration
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT03495674
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer
Not Applicable
Active, not recruiting
- Conditions
- Healthy SubjectHead and Neck CancerCutaneous Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03491176
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath